Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 25, 2015 7:47 AM ET

Biotechnology

Company Overview of PharmAbcine, Inc.

Company Overview

PharmAbcine, Inc., a biotechnology company, develops human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. It focuses primarily on the out-licensing of candidate therapeutics and clinical applications. The company develops TTAC0001, a human anti-angiogenic mAb against VEGFR-2(KDR); and dual specific antibody technologies, including DIG-body and PIG-body for therapeutic use. PharmAbcine, Inc. is headquartered in Daejeon, South Korea.

461-8, Daejeon BioventureTown

Jeonmin-Dong

Yuseong-Gu

Daejeon,  

South Korea

Phone:

82 4 2863 2017

Fax:

82 4 2863 2080

Key Executives for PharmAbcine, Inc.

Founder, Chief Executive Officer, President and Director
Co-Founder and Executive Vice President
Compensation as of Fiscal Year 2014.

PharmAbcine, Inc. Key Developments

PharmAbcine, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:00 AM

PharmAbcine, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

3SBio Inc. Enters into an Exclusive License with PharmAbcine, Inc

3SBio Inc. announced it has entered into an exclusive license with PharmAbcine Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. The deal included undisclosed upfront, milestone and royalty payments. Angiogenesis is correlated with disease progression and poor prognosis in many tumor types, such as colon, lung, breast and gastric cancers. VEGF and KDR (VEGFR2) are over-expressed in most malignant tumors, such as gastric, liver, NSCLC, ovarian, brain, colorectal, and breast cancers and their signaling is key regulator for tumor angiogenesis. Researchers from PharmAbcine have developed Tanibirumab, an anti-VEGFR2/KDR fully human monoclonal antibody to treat solid tumors. Tanibirumab binds KDR and blocks binding of VEGFR ligands, including VEGF-A, VEGF-C and VEGF-D. Consequently, Tanibirumab inhibits ligand-stimulated activation of KDR, therefore inhibits ligand-induced angiogenesis, proliferation, and migration of human endothelial cells. Tanibirumab had demonstrated anti-angiogenic efficacy against several cancer types and shown cross-species cross reactivity in multiple preclinical animal models including breast cancer, glioblastoma (GBM), lung cancer, colon cancer, and hepatocellular carcinoma (HCC). In November 2011, an open-label, non-randomized, dose-escalating phase I trial began to assess the safety and pharmacokinetics of Tanibirumab, administered intravenously, in 26 patients in Korea with advanced or metastatic cancer. The trial was finished in November 2013, with good safety and efficacy results. A phase II study of Tanibirumab in GBM is being planned.

PharmAbcine, Inc. Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014

PharmAbcine, Inc. Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 . Venue: London, United Kingdom.

Similar Private Companies By Industry

Company Name Region
PeopleBio, Inc. Asia
SunBio Corporation Asia
Hugel, Inc. Asia
GeneChem Inc. Asia
S.Biomedics Co., Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PharmAbcine, Inc., please visit www.pharmabcine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.